GNLX

Insider Trades

Name	Value	Action	Price	Last Price
Smalling RalphHead Of Regulatory $563192 shares SellJun 3, 2026 $2.93 $2.87
Thomas JohnDirector $30k10k shares SellJun 1, 2026 $2.98 $2.87
Cappello JosephChief Technical Officer $1.8k605 shares SellMay 11, 2026 $2.97 $2.87
Yu YongChief Scientific Officer $1.8k605 shares SellMay 11, 2026 $2.97 $2.87
Smalling RalphHead Of Regulatory $804270 shares SellMay 11, 2026 $2.98 $2.87
Zindrick ThomasPresident And CEO $8.2k2.8k shares SellMay 11, 2026 $2.94 $2.87

News

globenewswire.comGenelux Corporation Reports First Quarter Financial Results and Provides Business Updatesglobenewswire.comMay 7

Trade GNLX

About Genelux Corporation

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

CEO: Thomas D. Zindrick
IPO Date: Jan 26, 2023

Market Data

Open: $2.88
High: $2.98
Low: $2.83
Volume: 98.8K
Avg Volume: 189.3K
52W High: $8.54
52W Low: $2.29

Valuation

Market Cap: $111.5M
Enterprise Value: $104.8M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$26.4M
Revenue: $8K
Net Income: -$32.1M
Cash: $5.3M
Debt: $1.7M

Events

EarningsAug 6

EPS est. -0.2